Post-Doctoral position

The Institut Curie Research Center is a major player in the research and fight against cancer. It consists of a Hospital Group and a Research Center of more than 1000 employees with a strong international representativeness. The objective of the Research Center is to develop basic research and to use the knowledge produced to improve the diagnosis, prognosis, and therapeutics of cancers as part of the continuum between basic research and innovation serving the patient.LaboratoryThe research group DNA repair mechanisms in cancers (Ceccaldi Lab, https://institut-curie.org/team/ceccaldi) is seeking a post-doctoral researcher driving cutting-edge research projects aiming at understanding the mechanisms regulating genome stability.In recent years, our team has made significant contributions to the field of genome stability and tumor biology. Focusing on compensatory mechanisms employed by cancer cells with defects in homologous recombination (HR)-mediated repair, we shed light on new mechanisms and pathways controlling genome stability and HR-deficient tumor survival.From a translational point of view, our group has identified (and developed inhibitors against) new drug targets for the treatment of breast and ovarian tumors and highlighted the importance of studying the relationships between the different DNA repair pathways to better understand their interaction and exploit them for therapeutic purposes. Our long-term research goals hinge on the critical need for: New scientific approaches to discover additional regulators and effectors of genome stability,Basic understanding of interconnections between DNA repair processes, andNew drug development and biomarkers for anticancer targeted therapy.Recent publications from the teamZhou, J. et al. A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors. Nature Cancer, 2021.Gelot, C. et al. Pol? is phosphorylated by PLK1 to repair double-strand breaks in mitosis. Nature, 2023.Kovacs, M. T. et al. DNA damage induces nuclear envelope rupture through ATR-mediated phosphorylation of lamin A/C. Molecular Cell, 2023.Musiani, D. et al. SMUG1 trapping at unprocessed uracil upon UNG inhibition triggers homologous recombination and selectively kills BRCA1/2-deficient tumors. In revision, 2024.MissionsTo investigate new mechanisms that regulate the DNA damage response and repair pathways. A key aspect of the project will focus on evaluating the role of these mechanisms in tumor progression.Prospective postdoc applicants should have a Ph.D. degree in molecular biology, biochemistry, or genetics. The ideal applicant has further expertise in proteomics or microscopy. They should have a strong publication record with at least one first-author paper published in a high-profile journal, allowing them to apply for competitive stipends/fellowships and to eventually proceed towards an independent academic research position. Great communication skills are needed, together with appropriate organizational capacity.Professional English and/or French level required.All our opportunities are open to people with disabilities.Contract informationType of contract: Fixed-term contractStarting date: From November 2024Duration: 3 yearsWorking time: Full time / 211 days per yearRemuneration: according to the current gridsBenefits: Collective catering, reimbursement of transportation fees up to 70%, supplementary health insuranceLocation of the position: ParisContactPlease send your application including your CV, a letter of motivation explaining why you would like to join our team, and contact information of at least two referees.Publication date: August 2024Applications will be considered as they are received and until a candidate is selected.Institut Curie is an inclusive, equal opportunity employerand is dedicated to the highest standards of research integrity. #J-18808-Ljbffr